ÂÜÀòÂÒÂ×

Sue O’Dorisio, MD PhD is a Distinguished Professor of Pediatrics at the University of Iowa and a world-renowned leader in the adaptation of receptor-targeted image-guided radionuclide therapies for pediatric patient care. Dr. O’Dorisio earned a BS in Mathematics from Creighton University, an MS and PhD in Biochemistry from the University of Nebraska, and an MD cum laude from the Ohio State University, Columbus, OH. Dr. O’Dorisio is co-author of the joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors and The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary thyroid cancer. Dr. O’Dorisio has served as Principal Investigator on numerous National Cancer Institute (NCI) supported clinical and preclinical investigations and is the Principal Investigator of the University of Iowa NCI funded ($10M) Specialized Program of Research Excellence in Neuroendocrine Tumors (NET SPORE). This program under Dr. O’Dorisio’s leadership is recognized as the only NET SPORE funded by the NCI in the United States and the University of Iowa is also a non-European based European Neuroendocrine Tumor Society Center of Excellence. Dr. O’Dorisio has been Principal Investigator on numerous investigator-initiated INDs for radionuclide therapy trials for pediatrics and brings a wealth of knowledge and understanding to the introduction of Viewpoint products for pediatric indications of neuroblastoma, medulloblastoma, paraganglioma, and pheochromocytoma.